Varinder S. Athwal
SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis
Athwal, Varinder S.; Pritchett, James; Llewellyn, Jessica; Martin, Katherine; Camacho, Elizabeth; Raza, Sayyid M.A.; Phythian-Adams, Alexander; Birchall, Lindsay J.; Mullan, Aoibheann F.; Su, Kim; Pearmain, Laurence; Dolman, Grace; Zaitoun, Abed M.; Friedman, Scott L.; MacDonald, Andrew; Irving, William L.; Guha, Indra N.; Hanley, Neil A.; Hanley, Karen Piper
Authors
James Pritchett
Jessica Llewellyn
Katherine Martin
Elizabeth Camacho
Sayyid M.A. Raza
Alexander Phythian-Adams
Lindsay J. Birchall
Aoibheann F. Mullan
Kim Su
Laurence Pearmain
Grace Dolman
Abed M. Zaitoun
Scott L. Friedman
Andrew MacDonald
William L. Irving
Professor NEIL GUHA neil.guha@nottingham.ac.uk
PROFESSOR OF HEPATOLOGY
Neil A. Hanley
Karen Piper Hanley
Abstract
Fibrosis and organ failure is a common endpoint for many chronic liver diseases. Much is known about the upstream inflammatory mechanisms provoking fibrosis and downstream potential for tissue remodeling. However, less is known about the transcriptional regulation in vivo governing fibrotic matrix deposition by liver myofibroblasts. This gap in understanding has hampered molecular predictions of disease severity and clinical progression and restricted targets for antifibrotic drug development. In this study we show the prevalence of SOX9 in biopsies from patients with chronic liver disease correlated with fibrosis severity and accurately predicted disease progression towards cirrhosis. Inactivation of Sox9 in mice protected against both parenchymal and biliary fibrosis, improved liver function and ameliorated chronic inflammation. SOX9 was downstream of mechanosignaling factor, YAP1. These data demonstrate a role for SOX9 in liver fibrosis and open the way for the transcription factor and its dependent pathways as new diagnostic, prognostic and therapeutic targets in patients with liver fibrosis.
Citation
Athwal, V. S., Pritchett, J., Llewellyn, J., Martin, K., Camacho, E., Raza, S. M., Phythian-Adams, A., Birchall, L. J., Mullan, A. F., Su, K., Pearmain, L., Dolman, G., Zaitoun, A. M., Friedman, S. L., MacDonald, A., Irving, W. L., Guha, I. N., Hanley, N. A., & Hanley, K. P. (in press). SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis. EMBO Molecular Medicine, 9(12), https://doi.org/10.15252/emmm.201707860
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 20, 2017 |
Online Publication Date | Nov 6, 2017 |
Deposit Date | Sep 22, 2017 |
Publicly Available Date | Nov 6, 2017 |
Journal | EMBO Molecular Medicine |
Print ISSN | 1757-4676 |
Electronic ISSN | 1757-4684 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 9 |
Issue | 12 |
DOI | https://doi.org/10.15252/emmm.201707860 |
Keywords | SOX9; YAP1; Liver fibrosis; Extracellular matrix; Hepatic stellate cells |
Public URL | https://nottingham-repository.worktribe.com/output/892753 |
Publisher URL | http://embomolmed.embopress.org/content/early/2017/11/06/emmm.201707860 |
Contract Date | Sep 22, 2017 |
Files
emmm.201707860.full.pdf
(3.4 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search